Phase II study of lenalidomide for the treatment of relapsed or refractory Hodgkin's lymphoma

Trial Profile

Phase II study of lenalidomide for the treatment of relapsed or refractory Hodgkin's lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 07 Jun 2012 Planned end date changed from 1 Sep 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Planned end date changed from 1 Mar 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top